Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review

Background: The burden of community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae (pneumococcus) among adults in Europe is poorly defined. Methods: Structured searches of PubMed were conducted to identify the incidence of pneumococcal CAP among adults across Europe. Results: The overal...

ver descrição completa

Detalhes bibliográficos
Autores: Torres Martí, Antoni, Cillóniz, Catia, Blasi, Francesco, Chalmers, James D., Gaillat, Jacques, Dartois, Nathalie, Schmitt, Heinz-Josef, Welte, Tobias
Tipo de documento: artigo
Estado:Versión aceptada para publicación
Data de publicação:2018
País:España
Recursos:Universidad de Barcelona
Repositório:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/136598
Acesso em linha:https://hdl.handle.net/2445/136598
Access Level:Acceso aberto
Palavra-chave:Pneumònia adquirida a la comunitat
Pneumococs
Community-acquired pneumonia
Streptococcus pneumonia
Descrição
Resumo:Background: The burden of community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae (pneumococcus) among adults in Europe is poorly defined. Methods: Structured searches of PubMed were conducted to identify the incidence of pneumococcal CAP among adults across Europe. Results: The overall incidence rates for CAP was 68-7000 per 100,000 and the incidence in hospitalised CAP cases of all causes was 16-3581 per 100,000. In general the incidence of CAP increased consistently with age. Available data indicated higher burdens of pneumococcal CAP caused in groups with more comorbidities. Most cases of pneumococcal CAP (30%-78%) were caused by serotypes covered by PCV13 vaccine; the incidence of PCV13-related pneumonia decreased after the introduction of childhood vaccination. Conclusions: We observed a high burden adult pneumococcal CAP in Europe despite use of the 23-valent pneumococcal polysaccharide vaccine, particularly in elderly patients with comorbidities. CAP surveillance presented wide variations across Europe. Pneumococcal CAP has to be monitored very carefully due to the possible effect of current vaccination strategies.